[1] 沈晨涛,夏亚林,盛烨萍,等.儿童免疫性血小板减少症复发危险因素的调查及其预测模型的构建[J].基础医学与临床,2024,44:84-91. [2] He S, Fan C, Ma J, et al. Platelet transfusion in patients with sepsis and thrombocytopenia: a propensity score-matched analysis using a large ICU database[J]. Front Med (Lausanne), 2022,9:830177. doi: 10.3389/fmed.2022.830177. [3] 中国输血协会人类组织抗原专业委员会,中国输血协会免疫血液学专业委员会,张志欣,等.免疫性血小板输注无效的判定及临床实践专家共识[J].临床输血与检验,2022,24:273-278. [4] 刘界明.急性白血病患者单采血小板输注的疗效及相关因素分析[J].大医生, 2023, 8:114-117. [5] 完晓菊,陈洋,曹媛,等.交叉配型血小板在血液病患者移植后血小板输注无效中的应用[J].安徽医学, 2023, 44:891-894. [6] 张之南,沈悌.血液病诊断及疗效标准[M] (第三版).北京:科学出版社,2007:172-176. [7] Boothby AB, Tanner MK, Alswied A, et al. Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients[J]. Blood Adv, 2024,8:4689-4699. [8] Huisman EJ, Holle N, Schipperus M, et al. Should HLA and HPA-matched platelet transfusions for patients with Glanzmann Thrombasthenia or Bernard-Soulier syndrome be standardized care? A Dutch survey and recommendations[J]. Transfusion, 2024,64:824-838. [9] Patel P, Michael JV, Naik UP, et al. Platelet FcγRIIA in immunity and thrombosis: Adaptive immunothrombosis[J]. J Thromb Haemost, 2021,19:1149-1160. [10] Panch SR, Guo L, Vassallo R. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management[J]. Blood Rev, 2023,62:101135.doi:10.1016/j.blre.2023.101135. [11] Matsui R, Hagino T, Tsuno NH, et al. Does time of CCI measurement affect the evaluation of platelet transfusion effectiveness?[J]. Transfus Apher Sci, 2021,60:103123. doi: 10.1016/j.transci.2021.103123. [12] 敬媛媛,王洁,刘娜,等.免疫性血小板输注无效患者的人类白细胞抗原/人类血小板抗原抗体分布特征及其对交叉配型效果的影响[J].北京医学,2022,44:163-167. |